Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,841 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 822 · Balance 37,297 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,019 · Balance 38,316 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 2,255 · Balance 40,571 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 4 · 2026-09-15 · Sale · Disposed 4,730 · Balance 35,841 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2029-11-20 | Direct | 6,574 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 822 · Balance 6,574 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 8,144 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 1,019 · Balance 8,144 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 18,032 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,255 · Balance 18,032 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 2,255 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,032 Underlying: Common Stock · 2,255 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 1,019 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,144 Underlying: Common Stock · 1,019 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 822 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,574 Underlying: Common Stock · 822 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,730 | $24.18 | $114,371.40 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,841 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,255 | $8.63 | $19,460.65 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,019 | $7.51 | $7,652.69 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 822 | $6.52 | $5,361.33 |
DisclosureSEC source: 0001628280-26-062490 · wk-form4_1789675580.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 2,255 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,287 Underlying: Common Stock · 2,255 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 1,019 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,163 Underlying: Common Stock · 1,019 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 822 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,396 Underlying: Common Stock · 822 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,730 | $26.18 | $123,834.71 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,475 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,255 | $8.63 | $19,460.65 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,019 | $7.51 | $7,652.69 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 822 | $6.52 | $5,361.33 |
DisclosureSEC source: 0001628280-26-058008 · wk-form4_1787173021.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 2,255 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,542 Underlying: Common Stock · 2,255 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 1,019 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,182 Underlying: Common Stock · 1,019 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 822 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,218 Underlying: Common Stock · 822 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,730 | $26.91 | $127,284.30 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,109 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,255 | $8.63 | $19,460.65 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,019 | $7.51 | $7,652.69 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 822 | $6.52 | $5,361.33 |
DisclosureSEC source: 0001628280-26-048641 · wk-form4_1784318483.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 635 | $25.67 | $16,300.45 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · nonDerivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,743 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 2,255 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · derivative · entry 8 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,797 Underlying: Common Stock · 2,255 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 1,019 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,201 Underlying: Common Stock · 1,019 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 822 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,040 Underlying: Common Stock · 822 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,096 | $24.41 | $99,980.49 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,378 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.095 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,255 | $8.63 | $19,460.65 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,019 | $7.51 | $7,652.69 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 822 | $6.52 | $5,361.33 |
DisclosureSEC source: 0001628280-26-044079 · wk-form4_1781743212.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $21.23 | $0.00 |
DisclosureSEC source: 0001628280-26-042044 · wk-form4_1781054477.xml · derivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042044 · wk-form4_1781054477.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,378 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| May 01, 2026 Filed May 6, 2026 00:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,144 | $22.99 | $164,219.84 |
DisclosureSEC source: 0001801050-26-000002 · wk-form4_1778026885.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,600 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $23.88 | $238,801.00 |
DisclosureSEC source: 0001628280-26-023736 · wk-form4_1775252777.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,744 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.61 to $24.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $25.65 | $256,518.00 |
DisclosureSEC source: 0001628280-26-014639 · wk-form4_1772658986.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.37 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:23 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $25.05 | $250,483.00 |
DisclosureSEC source: 0001628280-26-005567 · wk-form4_1770250980.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $28.96 | $289,606.00 |
DisclosureSEC source: 0001628280-26-000969 · wk-form4_1767738714.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.905 to $29.17, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:23 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $30.21 | $302,133.00 |
DisclosureSEC source: 0001801050-25-000008 · wk-form4_1764800618.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $29.85 to $30.5650, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $25.27 | $252,669.00 |
DisclosureSEC source: 0001801050-25-000007 · wk-form4_1762385048.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.10 to $25.4298, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 9,538 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001801050-25-000005 · wk-form4_1759525315.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,538 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 462 | $18.92 | $8,742.29 |
DisclosureSEC source: 0001801050-25-000005 · wk-form4_1759525315.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.84 to $19.038, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,538 | $18.92 | $180,484.71 |
DisclosureSEC source: 0001801050-25-000005 · wk-form4_1759525315.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,206 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.84 to $19.038, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 9,538 | $1.68 | $16,029.56 |
DisclosureSEC source: 0001801050-25-000005 · wk-form4_1759525315.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-25-000132 · wk-form4_1757025659.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $15.64 | $156,383.00 |
DisclosureSEC source: 0001787306-25-000132 · wk-form4_1757025659.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,206 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.45 to $15.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000132 · wk-form4_1757025659.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 3,890 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-25-000115 · wk-form4_1754432914.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,890 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 6,110 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001787306-25-000115 · wk-form4_1754432914.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,110 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,890 | $14.30 | $55,620.00 |
DisclosureSEC source: 0001787306-25-000115 · wk-form4_1754432914.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,206 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 3,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000115 · wk-form4_1754432914.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,110 | $14.30 | $87,362.00 |
DisclosureSEC source: 0001787306-25-000115 · wk-form4_1754432914.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,206 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.